We came across a bullish thesis on BioNTech SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ ...

Kylie Jimenez is a seasoned global HR executive with more than 20 years of experience in shaping and scaling international organizations. She will join BioNTech from the international manufacturing ...

Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 vaccines.

BioNTech has initiated a Phase III clinical trial for its oncology candidate BNT324 in metastatic castration-resistant prostate cancer, aiming to compare the drug against current standard chemotherapy ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief executive officer saying he would consider a deal with a partner that gets ...

German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...

A key asset in this strategy, BNT113, recently achieved a critical regulatory milestone. On January 21, 2026, the U.S. Food and Drug Administration (FDA) granted "Fast Track" designation to this ...

BioNTech (BNTX) has drawn fresh attention after recent share price moves, with the stock up around 9% over the past week and around 16% over the past month, inviting closer scrutiny from investors.

The University of Pennsylvania, German biotech firm BioNTech, and Osage University Partners, a Bala Cynwyd venture capital ...

Strategic collaborations with partners such as Bristol-Myers Squibb and Genentech are intended to accelerate progress. While the pipeline is broadening, management notes that none of the oncology ...

BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic. Also Read: FDA ...

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine ...